✦ LIBER ✦

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo

✍ Scribed by Landmeier, S; Altvater, B; Pscherer, S; Meltzer, J; Sebire, N; Pule, M; Vera, J; Hotfilder, M; Juergens, H; Vormoor, J

Book ID: 109887367
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 343 KB
Volume: 24
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2010.38

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Synergistic and persistent effect of T-c

Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma

✍ Keichiro Mihara; Kazuyoshi Yanagihara; Misato Takigahira; Akira Kitanaka; Chihay 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 587 KB

Chimeric, divalent and tetravalent anti-

Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines

✍ Xiao-Yun Liu; Laurentiu M. Pop; Lydia Tsai; Iliodora V. Pop; Ellen S. Vitetta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 295 KB

## Abstract CD19 is an attractive therapeutic target for treating human B‐cell tumors. In our study, chimeric (c) divalent (cHD37) and tetravalent (cHD37‐DcVV) anti‐CD19 monoclonal antibodies (MAbs) were constructed, expressed and evaluated for their binding to human 19‐positive (CD19^+^) tumor cel

Dramatic Regression of Chronic Lymphocyt

Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation

✍ J.N. Kochenderfer; M.E. Dudley; I. Maric; S.A. Feldman; R. Salit; N.M. Hardy; P. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB